Clear Cell Sarcoma Foundation

Survivorship is more than a milestone. It reflects every step of the journey including the diagnosis, treatment, recovery, and living beyond cancer. It is a reminder of the progress made in care and research, and of the communities that support patients and families along the way.

At CCSF, we stand with survivors and all those impacted by Clear Cell Sarcoma, celebrating their strength while continuing to push for awareness, research, and better outcomes.

This month and every month, we honor survivors and the lives they inspire.

Learn more about our warriors here: https://www.clearcellsarcoma.org/patients

We encourage you to share your story here: https://www.jotform.com/form/241687356781166

Some studies are combining immunotherapy (which helps the immune system fight cancer) with targeted drugs.

One combination being studied is: nivolumab + sunitinib

Early results suggest:

- Longer time before cancer growth compared to chemotherapy
- Some patients benefit more than others
- Immune markers may help predict who responds best

👉 What this means: The immune system may play a bigger role in treating CCS than previously thought.

Read more about research studies in CCS here: https://www.clearcellsarcoma.org/research

Training immune cells to find cancer -->

Researchers are testing a new type of treatment that “guides” immune cells directly to cancer cells.

One example is Tebentafusp, which:

- Directs T-cells to attack cancer cells more precisely
- Is already approved for another rare cancer
- Is now being tested in CCS clinical trials

👉 What this means: Instead of broadly stimulating the immune system, this therapy helps immune cells find the tumor more directly.

Read more here: https://www.clearcellsarcoma.org/research

Learn more about Phase II trial of Tebentafusp here: https://clinicaltrials.gov/study/NCT06942442?cond=Clear%20Cell%20Sarcoma&aggFilters=status:rec&rank=2